Evidence map›Paper›PMID 28873013›Full record

ArticleCell cycle (Georgetown, Tex.)2017

Involvement of the specific nucleolar protein SURF6 in regulation of proliferation and ribosome biogenesis in mouse NIH/3T3 fibroblasts.

Anastasiia Moraleva, Charalambos Magoulas, Mikhail Polzikov, Sabine Hacot, Hichem C Mertani, Jean-Jacques Diaz, Olga Zatsepina

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. METTL3/YTHDF1-Driven SURF6 Promotes Prostate Cancer Stemness via CDK4.Journal of cellular and molecular medicine · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. The Time-Resolved Salt Stress Response ofInternational journal of molecular sciences · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Nucleophosmin in Its Interaction with Ligands.International journal of molecular sciences · 2020
    Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Anastasiia Moralevaa Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences , Moscow , Russian Federation.
Charalambos Magoulasb Centre for Investigative and Diagnostic Oncology, Department of Natural Sciences, School of Science and Technology , Middlesex University , London , United Kingdom.ORCID http://orcid.org/0000-0002-4396-7700
Mikhail Polzikova Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences , Moscow , Russian Federation.ORCID http://orcid.org/0000-0001-5345-0230
Sabine Hacotc Centre de Recherche en Cancérologie de Lyon, UMR INSERM 1052-CNRS 5286, Centre Léon Bérard , Université Claude Bernard Lyon I, Université de Lyon , Lyon , France.
Hichem C Mertanic Centre de Recherche en Cancérologie de Lyon, UMR INSERM 1052-CNRS 5286, Centre Léon Bérard , Université Claude Bernard Lyon I, Université de Lyon , Lyon , France.
Jean-Jacques Diazc Centre de Recherche en Cancérologie de Lyon, UMR INSERM 1052-CNRS 5286, Centre Léon Bérard , Université Claude Bernard Lyon I, Université de Lyon , Lyon , France.
Olga Zatsepinaa Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences , Moscow , Russian Federation.
Université Claude Bernard Lyon 1 · FRInstitute of Bioorganic Chemistry · RUMiddlesex University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The nucleolar proteins which link cell proliferation to ribosome biogenesis are regarded to be potentially oncogenic. Here, in order to examine the involvement of an evolutionary conserved nucleolar protein SURF6/Rrp14 in proliferation and ribosome biogenesis in mammalian cells, we established stably transfected mouse NIH/3T3 fibroblasts capable of conditional overexpression of the protein. Cell proliferation was monitored in real-time, and various cell cycle parameters were quantified based on flow cytometry, Br-dU-labeling and conventional microscopy data. We show that overexpression of SURF6 accelerates cell proliferation and promotes transition through all cell cycle phases. The most prominent SURF6 pro-proliferative effects include a significant reduction of the population doubling time, from 19.8 ± 0.7 to 16.2 ± 0.5 hours (t-test, p < 0.001), and of the length of cell division cycle, from 17.6 ± 0.6 to 14.0 ± 0.4 hours (t-test, p < 0.001). The later was due to the shortening of all cell cycle phases but the length of G1 period was reduced most, from 5.7 ± 0.4 to 3.8 ± 0.3 hours, or by ∼30%, (t-test, p < 0.05). By Northern blots and qRT-PCR, we further showed that the acceleration of cell proliferation was concomitant with an accumulation of rRNA species along both ribosomal subunit maturation pathways. It is evident, therefore, that like the yeast homologue Rrp14, mammalian SURF6 is involved in various steps of rRNA processing during ribosome biogenesis. We concluded that SURF6 is a novel positive regulator of proliferation and G1/S transition in mammals, implicating that SURF6 is a potential oncogenic protein, which can be further studied as a putative target in anti-cancer therapy.

Indexed as

Organelle BiogenesisAnimalsCell CycleCell ProliferationCell SurvivalFibroblastsFlow CytometryMiceNIH 3T3 CellsNuclear ProteinsPhenotypeRibosomesRNA, RibosomalTime FactorsTransfectionNuclear ProteinsRNA, RibosomalSurf6 protein, mousecell cyclemouse NIH/3T3 fibroblastsnucleolusproliferationribosome biogenesisrRNA processingSURF6

Identifiers

PMID28873013
PMCPMC5638364
OpenAlexW2753658450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.